These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8842337)

  • 1. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions.
    Kito G; Ito K; Shiomi M
    Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats.
    Kawamura M; Terashita Z; Okuda H; Imura Y; Shino A; Nakao M; Nishikawa K
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1664-9. PubMed ID: 8371164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
    Hayashi N; Yamamoto S; Kometani M; Nakao K
    Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventricular failure.
    Murakami M; Inada Y; Tazawa S; Nakao K; Komatsu H
    Arzneimittelforschung; 1997 Oct; 47(10):1099-103. PubMed ID: 9368701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells.
    Flesch M; Ko Y; Seul C; Düsing R; Feltkamp H; Vetter H; Sachinidis A
    Eur J Pharmacol; 1995 Apr; 289(2):399-402. PubMed ID: 7621917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension.
    Ito K; Shiomi M; Kito G
    Hypertens Res; 1995 Mar; 18(1):69-75. PubMed ID: 7584913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
    Inada Y; Murakami M; Kaido K; Nakao K
    Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.
    Kim S; Ohta K; Hamaguchi A; Omura T; Yukimura T; Miura K; Inada Y; Ishimura Y; Chatani F; Iwao H
    J Pharmacol Exp Ther; 1995 Apr; 273(1):509-15. PubMed ID: 7714806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
    Takeda K; Fujita H; Nakamura K; Uchida A; Tanaka M; Itoh H; Nakata T; Sasaki S; Nakagawa M
    Blood Press Suppl; 1994; 5():94-8. PubMed ID: 7889211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
    Okamura M; Konishi Y; Nishimura M; Umetani N; Iwai J; Negoro N; Inoue T; Takeda T; Kanayama Y
    Blood Press Suppl; 1994; 5():75-8. PubMed ID: 7889207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation.
    Mackenzie HS; Troy JL; Rennke HG; Brenner BM
    J Hypertens Suppl; 1994 Nov; 12(9):S11-6. PubMed ID: 7884578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The angiotensin receptor antagonist 2-ethoxy-1-[[2'-(1H- tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV11974) attenuates the tubuloglomerular feedback response during NO synthase blockade in rats.
    Kawata T; Hashimoto S; Koike T
    J Pharmacol Exp Ther; 1996 May; 277(2):572-7. PubMed ID: 8627533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects.
    Ogihara T; Nagano M; Mikami H; Higaki J; Kohara K; Azuma J; Aoki T; Hamanaka Y
    Clin Ther; 1994; 16(1):74-86. PubMed ID: 8205603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension.
    Kawabata M; Takabatake T; Ohta H; Nakamura S; Hara H; Ohta K; Takakuwa H; Han WH; Kobayashi K
    Blood Press Suppl; 1994; 5():117-21. PubMed ID: 7889193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
    Nishikawa K; Inada Y; Shibouta Y; Wada T; Ojima M; Kubo K; Naka T
    Blood Press Suppl; 1994; 5():7-14. PubMed ID: 7889205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part I: Respiratory and cardiovascular systems.
    Hirohashi M; Takasuna K; Yamashita N; Tamura K
    Arzneimittelforschung; 1991 Jan; 41(1):9-18. PubMed ID: 1675573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.